Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis

Overview

This clinical trial will evaluate the efficacy and safety of Clobex® (clobetasol propionate) Spray 0.05% and Vectical™ (calcitriol) Ointment 3 µg/g over a four week period of use in one of two different regimens: 1. Vectical™ Ointment treatment, twice daily on weekdays (Mon – Fri) and Clobex® Spray treatment twice daily on weekends (Sat – Sun) for 28 days 2. Clobex® Spray once each morning and Vectical™ Ointment once each evening for 28 days

Full Title of Study: “An Open-label, Multi-center, Randomized, Evaluator-Blinded Study to Evaluate the Safety and Efficacy of Two Treatment Regimens Involving Vectical™ (Calcitriol) Ointment 3 µg/g and Clobex® (Clobetasol Propionate) Spray, 0.05% in the Treatment of Moderate Plaque Psoriasis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: March 2010

Interventions

  • Drug: Vectical™ Ointment weekdays and Clobex® Spray weekends regimen
    • Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
  • Drug: Clobex® Spray morning and Vectical™ Ointment evening regimen
    • Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days

Arms, Groups and Cohorts

  • Other: 1) Vectical™ Ointment and Clobex® Spray
    • Vectical™ Ointment weekdays & Clobex® Spray weekends regimen
  • Other: 2) Clobex® Spray and Vectical™ Ointment
    • Clobex® Spray morning and Vectical™ Ointment evening regimen

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants Who Were a Success (Clear/Almost Clear) of Plaque Psoriasis at Week 4 Based on the Overall Disease Severity (ODS), Full Ordinal Scale From Baseline to Week 4
    • Time Frame: Baseline to Week 4
    • Number of participants who were a success (Clear/Almost Clear) of Plaque Psoriasis at week 4 based on the Overall Disease Severity (ODS), full ordinal scale from baseline to week 4. Overall Disease Severity is evaluated on a scale from 0 – 4 (0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate, 4 = Severe/Very Severe) with 0 being best and 4 being worst.

Secondary Measures

  • Number of Participants Who Were a Success (Clear/Almost Clear) of Plaque Psoriasis at Week 2 Based on the Overall Disease Severity (ODS), Dichotomized Scale From Baseline to Week 2
    • Time Frame: Baseline to week 2
    • Number of participants who were a success (Clear/Almost Clear) of Plaque Psoriasis at Week 2 based on the Overall Disease Severity (ODS), dichotomized scale from Baseline to Week 2. Overall Disease Severity is evaluated on a scale from 0 – 4 (0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate, 4 = Severe/Very Severe) with 0 being best and 4 being worst.
  • Number of Participants in Each Category of the Global Assessment of Improvement (GAI) Scale From Baseline to Week 4
    • Time Frame: Baseline to Week 4
    • Number of participants in each category of the Global Assessment of Improvement (GAI) Scale from Baseline to Week 4. The Global Assessment of Improvement is evaluated on a scale from -1 to 4 (-1 = Symptoms worse, 0 = No change, 1 = Minimal Improvement, 2 = Definite Improvement, 3 = Considerable Improvement and 4 = Clearing) with -1 being worst and 4 being best.
  • Number of Participants With a Decrease in Signs of Psoriasis (Erythema) Scores From Baseline to Week 4
    • Time Frame: Baseline to Week 4
    • Number of participants with a decrease in Signs of Psoriasis (Erythema) scores from Baseline to Week 4. Signs of Psoriasis (Erythema) are evaluated on a scale from 0 – 4 (0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate, 4 = Severe/Very Severe with 0 being best and 4 being worst.
  • Number of Participants With Decrease in Signs of Psoriasis (Scaling) Scores From Baseline to Week 4
    • Time Frame: Baseline to Week 4
    • Number of participants with decrease in Signs of Psoriasis (Scaling) scores from Baseline to Week 4. Signs of Psoriasis (Scaling) are evaluated on a scale from 0 – 4 (0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate, 4 = Severe/Very Severe) with 0 being best and 4 being worst.
  • Number of Participants With Decrease in Signs of Psoriasis (Plaque Elevation) Scores From Baseline to Week 4
    • Time Frame: Baseline to Week 4
    • Number of participants with decrease in Signs of Psoriasis (Plaque Elevation) scores from Baseline to Week 4. Signs of Psoriasis (Plaque Elevation) are evaluated on a scale from 0 – 4 (0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate, 4 = Severe/Very Severe) with 0 being best and 4 being worst.
  • Median Percent (%) Change From Baseline in % Treatable BSA (Body Surface Area) From Baseline to Week 4
    • Time Frame: Baseline to Week 4
    • Median percent (%) change from baseline in % treatable BSA (Body Surface Area) from Baseline to Week 4
  • Mean Change From Baseline Scores for the Koo-Menter Psoriasis Index 12-item Quality of Life Questionnaire (PQOL-12) From Baseline to Week 4
    • Time Frame: Baseline to Week 4
    • Mean change from baseline scores for the Koo-Menter Psoriasis Index 12-item Quality of Life Questionnaire (PQOL-12) from Baseline to Week 4. The Koo-Menter Psoriasis Index is a questionnaire with 12 questions that can be used to assess the effect that psoriasis has on a patient’s overall quality of life. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst.
  • Number of Participants Who Responded to the Categories of Possible Answers to the Subject’s Satisfaction Survey Question “The Treatment Program Was Easy to Follow” at Week 4
    • Time Frame: Baseline and Week 4
    • Number of participants who responded to the categories of possible answers to the Subject’s Satisfaction Survey question “The treatment program was easy to follow” at Week 4. Categories of possible answers include Strongly agree, Moderately agree, No opinion, Moderately disagree, and Strongly disagree.
  • Number of Participants Who Responded to the Categories of Possible Answers to the Subject’s Satisfaction Survey Question “I am Satisfied With my Appearance” at Week 4
    • Time Frame: Week 4
    • Number of participants who responded to the categories of possible answers to the Subject’s Satisfaction Survey question “I am Satisfied with my Appearance” at Week 4. Categories of possible answers include Strongly agree, Moderately agree, No opinion, Moderately disagree, and Strongly disagree.
  • Number of Participants Who Responded to the Categories of Possible Answers to the Subject’s Satisfaction Survey Question “I am Satisfied With the Results of This Treatment Program” at Week 4
    • Time Frame: Week 4
    • Number of participants who responded to the categories of possible answers to the Subject’s Satisfaction Survey question “I am satisfied with the results of this treatment program” at Week 4. Categories of possible answers include Strongly agree, Moderately agree, No opinion, Moderately disagree, and Strongly disagree.
  • Number of Participants Who Responded to the Categories of Possible Answers to the Subject’s Satisfaction Survey Question “I Would Use This Treatment Program Again if Recommended by the Dermatologist” at Week 4
    • Time Frame: Week 4
    • Number of participants who responded to the categories of possible answers to the Subject’s Satisfaction Survey question “I would use this treatment program again if recommended by the dermatologist” at Week 4. Categories of possible answers include Strongly agree, Moderately agree, No opinion, Moderately disagree, and Strongly disagree.
  • Number of Participants With Tolerability Assessments Resulting in Adverse Events From Baseline to Week 4
    • Time Frame: Baseline to Week 4
    • Number of participants with Tolerability Assessments resulting in Adverse Events from baseline to week 4. Tolerability assessments (Pruritus, telangiectasias, and stinging/burning) are evaluated on a scale from 0 – 3 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 3 being worst. Skin atrophy and folliculitis are evaluated as absent or present. Changes in tolerability assessments that require a dose modification or concomitant medications/therapy are recorded as adverse events.

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female subjects aged 18 to 80 years inclusive – Subjects with an Overall Disease Severity of 3 (moderate) – Subjects with 3% – 10% treatable BSA (Body Surface Area) excluding scalp, face, groin, axillae and/or other intertriginous areas – For concurrent medications, type and dose must have been stable for at least 3 months prior to study entry and not expected to change during the study. Subjects receiving treatment with beta-blockers or lithium, whose dose has been stable for at lest 6 months and who have shown no worsening of their psoriasis, may be included in the study, at the discretion of the investigator Exclusion Criteria:

  • Subjects with intakes of more than 2,000 IU/day (50 mcg/day) of vitamin D (tolerable upper intake level) and/or more than 1,000 mg/day of calcium – Subjects whose psoriasis involves only the scalp, face, groin, axillae, and/or other intertriginous areas – Subjects with a wash-out period for topical treatment less than 30 days (Any steroid containing medication, dovonex, anthralin, tar and/or UVB treatment) – Subjects with a wash-out period for systemic treatment less than 12 weeks (corticosteroids, biologics and/or PUVA treatment; Examples of these therapies include, but are not limited to PUVA, Soriatane, Cyclosporine, Hydroxyurea, Mycophenolate mofetil, Sulfasalazine, Azathioprine, Alefacept, Efalizumab, Adalimumab, Etanercept, Infliximab, Rituximab, and Methotrexate) – Subjects with non-plaque psoriasis or other related diseases not classified as plaque psoriasis – Subjects who foresee intensive UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Galderma R&D
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ronald W Gottschalk, MD, Study Director, Galderma R&D

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.